Checkmate 577: Disease-Free Survival and Recurrence in Nivolumab Group

A 5.5 KB Excel file from the Checkmate 577 clinical trial, authored by Tamara J. Huizer and last updated in June 2026. It contains data on disease-free survival and the proportion of patients with recurrent disease specifically for the nivolumab treatment group. The dataset is shared under a CC-BY-4.0 license on the figshare platform.

Use Cases

• Analyze disease-free survival outcomes based on the nivolumab treatment group data.
• Calculate the proportion of patients with recurrent disease based on the trial results.
• Compare efficacy metrics from the Checkmate 577 trial for secondary research or meta-analysis.

Strengths

• Data is from a named, published clinical trial (Checkmate 577).
• File is small (5.5 KB), ensuring quick download and easy inspection.
• License is clearly stated as CC-BY-4.0, permitting reuse with attribution.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The description metadata is limited to a single repeated sentence.

Provenance

Source

figshare, authored by Tamara J. Huizer.

Collection Method

Likely extracted or summarized from the Checkmate 577 clinical trial results.

Freshness

Last updated 2026-06-02 17:24:57; freshness should be verified.